title: Stereoselectivity and species difference in plasma protein binding of KE-298 and its metabolites.
abstract: In vitro protein binding of KE-298 and its plasma metabolites, deacetyl-KE-298 (M-1) and S-methyl-KE-298 (M-2), was high in rat (>97%), dog (>89%) and human plasma (>99%), respectively. Human serum albumin (>93%) was the main protein involved in the binding to plasma proteins, while the binding to human serum globulins was low (16-33%). The binding of KE-298 and its metabolites in all species of plasma was stereoselective. The (+)-(S)-enantiomers of these compounds bound rat, dog and human plasma proteins to a greater extent than did the (-)-(R)-enantiomers, except that the case of KE-298 was opposite in rat plasma. The stereoselective plasma levels of these compounds in rats, dogs, or humans would likely be due to stereoselective differences in binding to plasma albumin. The protein binding of M-1 in adjuvant-induced arthritis rat plasma was >97%, and the stereoselectivity was similar to the case of normal rat plasma. KE-298 and its metabolites remarkably displaced [14C]warfarin, which bound on albumin in a solution of diluted rat serum albumin. Similarly, there was a displacement of [14C]warfarin in solutions of dog and human serum albumin, and concomitantly the displacement of [14C]diazepam. [3H]Digitoxin was not displaced by any of the enantiomers in each albumin solution. No stereoselectivity was found in displacement by enantiomers of the three compounds. These results suggest that stereoselective protein binding can be attributed to quantitative differences in binding to albumin rather than to the different binding sites.
authors.affiliation: Department of Drug Metabolism, and Department of Pharmacology, Research Center, Taisho Pharmaceutical Co, Ltd, Omiya, Saitama, Japan. s14952@ccm.taisho.co.jp
authors.forename: H
authors.initials: H
authors.lastname: Endo
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: M
authors.initials: M
authors.lastname: Hasegawa
authors.forename: N
authors.initials: N
authors.lastname: Ohmi
authors.forename: N
authors.initials: N
authors.lastname: Horiuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Hamada
authors.forename: S
authors.initials: S
authors.lastname: Higuchi
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000097:blood* / Q000737:chemistry; D001169:Arthritis, Experimental / Q000188:drug therapy; D001665:Binding Sites; D001798:Blood Proteins / Q000378:metabolism; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D010666:Phenylpropionates / Q000097:blood* / Q000737:chemistry; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012709:Serum Albumin / Q000378:metabolism; D013045:Species Specificity; D013237:Stereoisomerism
chemical_list: D018501:Antirheumatic Agents; D001798:Blood Proteins; D010666:Phenylpropionates; D012709:Serum Albumin; C078547:esonarimod